Title : A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Pub. Date : 2014 Nov

PMID : 25081901






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conversely, KRAS-variant patients appeared to experience some improvement in disease control when cetuximab was added to their platinum-based regimen (log-rank P = 0.04). Platinum KRAS proto-oncogene, GTPase Homo sapiens
2 CONCLUSIONS: The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients. Platinum KRAS proto-oncogene, GTPase Homo sapiens